9. The pharmaceutical composition of claim 8, comprising about 31% by weight of AVICEL PH 102®.

10. The pharmaceutical composition according to any one of claims 1 to 9, further comprising a disintegrant.

11. The pharmaceutical composition of claim 10, wherein the disintegrant is croscarmellose sodium.

12. The pharmaceutical composition of claim 10, wherein the disintegrant is AC-DI-SOL®.

13. The pharmaceutical composition of claim 12, wherein the pharmaceutical composition comprises from about 1-5% by weight of AC-DI-SOL®.

14. The pharmaceutical composition according to any one of claims 1 to 13, wherein the pharmaceutical composition comprises about 10-20% ~~40-60%~~ by weight of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((*trans*)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one, or a pharmaceutically acceptable salt, isotopologue, or solid form thereof.

15. The pharmaceutical composition of claim 14, wherein the pharmaceutical composition comprises about 15% by weight of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((*trans*)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one or a pharmaceutically acceptable salt, isotopologue, or solid form thereof.

16. The pharmaceutical composition of claim 15, wherein the pharmaceutical composition comprises Form A of 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((*trans*)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-*b*]pyrazin-2(1*H*)-one.